Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer—A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib

Seattle Cancer Care Alliance Network Investigators

doi:10.1016/j.clbc.2018.12.008

Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer—A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib

Seattle Cancer Care Alliance Network Investigators

Hematology and Oncology

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

Chemotherapy remains the mainstay of metastatic triple negative breast cancer treatment; however, angiogenesis and epidermal growth factor receptor are potential targets. The present phase II clinical trial of nab-paclitaxel and bevacizumab, followed by maintenance therapy with bevacizumab and erlotinib, demonstrated progression-free survival similar to that with other regimens. Most patients experienced a partial response and received maintenance therapy, resulting in a significant break from cytotoxic chemotherapy.

Original language	English (US)
Journal	Clinical Breast Cancer
DOIs	https://doi.org/10.1016/j.clbc.2018.12.008
State	Published - Jan 1 2019

Keywords

Circulating endothelial cells
Circulating tumor cells
Erlotinib
Metastatic
Nab-paclitaxel bevacizumab
Triple negative breast cancer

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1016/j.clbc.2018.12.008

Fingerprint Dive into the research topics of 'Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer—A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib'. Together they form a unique fingerprint.

Cite this

Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer—A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib. / Seattle Cancer Care Alliance Network Investigators.

In: Clinical Breast Cancer, 01.01.2019.

Research output: Contribution to journal › Article › peer-review

@article{b0e466221ba844269081b908119f1e8f,

title = "Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer—A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib",

abstract = "Chemotherapy remains the mainstay of metastatic triple negative breast cancer treatment; however, angiogenesis and epidermal growth factor receptor are potential targets. The present phase II clinical trial of nab-paclitaxel and bevacizumab, followed by maintenance therapy with bevacizumab and erlotinib, demonstrated progression-free survival similar to that with other regimens. Most patients experienced a partial response and received maintenance therapy, resulting in a significant break from cytotoxic chemotherapy.",

keywords = "Circulating endothelial cells, Circulating tumor cells, Erlotinib, Metastatic, Nab-paclitaxel bevacizumab, Triple negative breast cancer",

author = "{Seattle Cancer Care Alliance Network Investigators} and Lynn Symonds and Hannah Linden and Vijayakrishna Gadi and Larissa Korde and Eve Rodler and Julie Gralow and Mary Redman and Kelsey Baker and Wu, {Quan (Vicky)} and Isaac Jenkins and Brenda Kurland and Mitchell Garrison and Julie Smith and Jeanne Anderson and {Van Haelst}, Carol and Jennifer Specht",

year = "2019",

month = jan,

day = "1",

doi = "10.1016/j.clbc.2018.12.008",

language = "English (US)",

journal = "Clinical Breast Cancer",

issn = "1526-8209",

publisher = "Elsevier",

}

TY - JOUR

T1 - Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer—A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib

AU - Seattle Cancer Care Alliance Network Investigators

AU - Symonds, Lynn

AU - Linden, Hannah

AU - Gadi, Vijayakrishna

AU - Korde, Larissa

AU - Rodler, Eve

AU - Gralow, Julie

AU - Redman, Mary

AU - Baker, Kelsey

AU - Wu, Quan (Vicky)

AU - Jenkins, Isaac

AU - Kurland, Brenda

AU - Garrison, Mitchell

AU - Smith, Julie

AU - Anderson, Jeanne

AU - Van Haelst, Carol

AU - Specht, Jennifer

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Chemotherapy remains the mainstay of metastatic triple negative breast cancer treatment; however, angiogenesis and epidermal growth factor receptor are potential targets. The present phase II clinical trial of nab-paclitaxel and bevacizumab, followed by maintenance therapy with bevacizumab and erlotinib, demonstrated progression-free survival similar to that with other regimens. Most patients experienced a partial response and received maintenance therapy, resulting in a significant break from cytotoxic chemotherapy.

AB - Chemotherapy remains the mainstay of metastatic triple negative breast cancer treatment; however, angiogenesis and epidermal growth factor receptor are potential targets. The present phase II clinical trial of nab-paclitaxel and bevacizumab, followed by maintenance therapy with bevacizumab and erlotinib, demonstrated progression-free survival similar to that with other regimens. Most patients experienced a partial response and received maintenance therapy, resulting in a significant break from cytotoxic chemotherapy.

KW - Circulating endothelial cells

KW - Circulating tumor cells

KW - Erlotinib

KW - Metastatic

KW - Nab-paclitaxel bevacizumab

KW - Triple negative breast cancer

UR - http://www.scopus.com/inward/record.url?scp=85060977590&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060977590&partnerID=8YFLogxK

U2 - 10.1016/j.clbc.2018.12.008

DO - 10.1016/j.clbc.2018.12.008

M3 - Article

C2 - 30737173

AN - SCOPUS:85060977590

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

ER -